Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries

SE Cooper, J Rosenblatt… - Clinical Infectious Diseases, 2022 - academic.oup.com
Long-acting injectable antiretroviral therapy (LAI-ART) for the treatment and prevention of
human immunodeficiency virus (HIV) holds great potential to shift treatment paradigms by …

[HTML][HTML] The influence of anticipated HIV stigma on health-related behaviors, self-rated health, and treatment preferences among people living with HIV in East Asia

F Yu, YH Hsiao, S Park, K Kambara, B Allan… - AIDS and Behavior, 2023 - Springer
Long-acting injectable regimens for HIV treatment have been developed which are less
frequent, more discreet, and more desirable for some people living with HIV (PLHIV) and …

Long‐acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for …

N Nguyen, B Lane, SA Golub… - Journal of the …, 2024 - Wiley Online Library
Introduction Approval of the first long‐acting injectable antiretroviral therapy (LAI ART)
medication heralded a new era of HIV treatment. However, the years since approval have …

Long-acting injectable antiretrovirals for HIV treatment: A multi-site qualitative Study of Clinic-Level Barriers to Implementation in the United States

T McCrimmon, LF Collins, A Perez-Brumer… - AIDS patient care and …, 2024 - liebertpub.com
Long-acting injectable antiretroviral therapy (LAI ART) has the potential to address
adherence obstacles associated with daily oral ART, leading to enhanced treatment uptake …

[HTML][HTML] Long-Acting Gel Formulations: Advancing Drug Delivery across Diverse Therapeutic Areas

H Omidian, RL Wilson - Pharmaceuticals, 2024 - mdpi.com
This multifaceted landscape of long-acting gels in diverse medical fields, aims to enhance
therapeutic outcomes through localized treatment and controlled drug release. The objective …

[HTML][HTML] Long-acting injectable therapy for people with HIV: looking ahead with lessons from psychiatry and addiction medicine

GG Edwards, A Miyashita-Ochoa, EG Castillo… - AIDS and Behavior, 2023 - Springer
Long-acting injectable antiretroviral medications are new to HIV treatment. People with HIV
may benefit from a treatment option that better aligns with their preferences, but could also …

Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV …

EM Sherman, AL Agwu, J Ambrosioni… - … : The Journal of …, 2024 - Wiley Online Library
Five long‐acting (LA) antiretrovirals (ARVs) are currently available in a limited number of
countries worldwide for HIV‐1 prevention or treatment—cabotegravir, rilpivirine, lenacapavir …

[HTML][HTML] Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States

XA Erguera, KA Koester, M Diaz Tsuzuki, KV Dance… - AIDS and Behavior, 2024 - Springer
Understanding the acceptability of long-acting injectable antiretroviral therapy (LAI-ART)
among people with HIV (PWH), especially priority populations, is essential for effective …

Considerations for the use of long-acting and extended-release agents during pregnancy and lactation

A Olagunju, J Mathad, A Eke… - Clinical Infectious …, 2022 - academic.oup.com
Long-acting agents hold significant promise for treating and preventing common illnesses,
including infections. Pharmacokinetic and safety data during pregnancy and lactation are …

Understanding treatment preferences among people living with HIV in Australia: a discrete choice experiment

S Fifer, T Kularatne, M Tan, F Drummond… - Patient preference and …, 2023 - Taylor & Francis
Purpose To better understand what is most important to people living with human
immunodeficiency virus (PLWH) when choosing their treatment. We assessed how PLWH …